Advanced search
Publication Cover
Expert Review of Molecular Diagnostics Volume 6, 2006 - Issue 3
Submit an article Journal homepage
220
Views
40
CrossRef citations to date
0
Altmetric
Review

Biomarkers for amyotrophic lateral sclerosis

Robert Bowser University of Pittsburgh, Department of Pathology, School of Medicine, ST S-420, 200 Lothrop Street, Pittsburgh, PA 15261, USA. [email protected]
,
Merit Cudkowicz Harvard Medical School, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA. [email protected]
&
Rima Kaddurah-Daouk Duke University Medical Center, Department of Psychiatry, Durham, NC, USA. [email protected]
Pages 387-398 | Published online: 09 Jan 2014

References

  • Cleveland DW, Rothstein J. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nature Rev. Neurosci.2, 806–819 (2001).
  • Strong MJ. The basic aspects of therapeutics in amyotrophic lateral sclerosis. Pharmacol. Ther.98, 379–414 (2003).
  • Testa D, Lovati R, Ferrarini M, Salmoiraghi F, Filippini G. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph. Lateral Scler. Other Motor Neuron Disord.5, 208–212 (2004).
  • Atkinson AJJ, Warren G, Colburn WA et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69, 89–95 (2001).
  • Coon KD, Dunckley T, Stephan DA. Biomarker identification in neurologic diseases: improving diagnostics and therapeutics. Expert Rev. Mol. Diagn.4, 361–375 (2004).
  • Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx1, 189–195 (2004).
  • Lewin DA, Weiner MP. Molecular biomarkers in drug development. Drug Discov. Today9, 976–983 (2004).
  • Cudkowicz M, Qureshi M, Shefner J. Measures and markers in amyotrophic lateral sclerosis. NeuroRx1, 273–283 (2004).
  • Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nature Rev. Drug Discov.2, 566–580 (2003).
  • Mitchell JD. Guidelines in motor neuron disease (MND)/amyotrophic lateral sclerosis (ALS) – from diagnosis to patient care. J. Neurol.247, 7–12 (2000).
  • Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord.1, 293–299 (2000).
  • Brooks BR. Diagnostic dilemmas in amyotrophic lateral sclerosis. J. Neurol. Sci.165(Suppl. 1), S1–S9 (1999).
  • Kennedy S. Proteomic profiling from human samples: the body fluid alternative. Toxicol. Lett.120, 379–384 (2001).
  • Cedarbaum J. Survival. Amyotroph. Lateral Scler. Other Motor Neuron Disord.5, 79–83 (2004).
  • Miller RG, Moore DH. ALS trial design: expectation and reality. Amyotroph. Lateral Scler. Other Motor Neuron Disord.5, 52–54 (2004).
  • Loi S, Buyse M, Sotiriou C, Cardoso F. Challenges in breast cancer clinical trial design in the postgenomic era. Curr. Opin. Oncol.16, 536–541 (2004).
  • Cooper R, Kaanders JH. Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls. Eur. J. Cancer41, 1261–1266 (2005).
  • Rosen DR, Siddique T, Patterson D et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature362, 59–62 (1993).
  • Gurney ME, Pu H, Chiu AY et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science264, 1772–1775 (1994).
  • Majoor-Krakauer D, Willems PJ, Hofman A. Genetic epidemiology of amyotrophic lateral sclerosis. Clin. Genet.63, 83–101 (2003).
  • Lindberg MJ, Bystrom R, Boknas N, Andersen PM, Oliveberg M. Systematically perturbed folding patterns of amyotrophic lateral sclerosis (ALS)-associated SOD1 mutants. Proc. Natl Acad. Sci. USA102, 9754–9759 (2005).
  • Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am. J. Hum. Genet.75, 933–947 (2004).
  • Yang Y, Hentati A, Deng H-X et al. The gene encoding Alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nature Genet.29, 160–165 (2001).
  • Hadano S, Hand CK, Osuga H et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nature Genet.29, 166–173 (2001).
  • Puls I, Jonnakuty C, LaMonte BH et al. Mutant dynactin in motor neuron disease. Nature Genet.33, 455–456 (2003).
  • Munch C, Sedlmeier R, Meyer T et al. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology63, 724–726 (2004).
  • LaMonte BH, Wallace KE, Holloway BA et al. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron34, 715–727 (2002).
  • Chen LN, Bennet CL, Huynh HM et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet.74, 1128–1135 (2004).
  • Hosler BA, Siddique T, Sapp PC et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA284, 1664–1669 (2000).
  • Traynor BJ, Zhang H, Shefner JM et al. Functional outcome measures as clinical trial endpoints in ALS. Neurology63, 1933–1935 (2004).
  • de Carvalho M, Chio A, Dengler R et al. Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph. Lateral Scler. Other Motor Neuron Disord.6, 17–28 (2005).
  • Andres PL, Hedlund W, Finison L et al. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology36, 937–941 (1986).
  • Stambler N, Charatran M, Cedarbaum J. Prognostic indicators of survival in ALS. Neurology50, 66–72 (1998).
  • Cudkowicz M, Shefner J, Schoenfeld D et al. A randomized, placebo-controlled trial of topiramate in patients with amyotrophic lateral sclerosis. Neurology61, 456–464 (2003).
  • Cudkowicz M, Zhang H, Qureshi M, Schoenfeld D. Maximum voluntary isometric contraction (MVIC). Amyotroph. Lateral Scler. Other Motor Neuron Disord.5, 84–85 (2004).
  • Beck M, Giess R, Wurffel W. Comparison of maximal voluntary isometric contraction and Drachman’s hand-held dynamometry in evaluating patients with amyotrophic lateral sclerosis. Muscle Nerve22, 1265–1270 (1999).
  • Sorensen EJ. Assessment of strength measurements. Amyotroph. Lateral Scler. Other Motor Neuron Disord.5, 86–89 (2004).
  • Sorenson EJ, Barkhaus PE, David W et al. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology61, 1503–1506 (2003).
  • Armon C, Brandstater ME. Motor unit number estimate-based rates of progression of ALS predict patient survival. Muscle Nerve22, 1571–1575 (1999).
  • Jillapalli D, Shefner JM. Single motor unit variability with threshold stimulation in patients with amyotrophic lateral sclerosi and normal subjects. Muscle Nerve30, 578–584 (2004).
  • Shefner JM, Cudkowicz ME, Zhang H et al. The use of statistical MUNE in a multicenter clinical trial. Muscle Nerve30, 463–469 (2004).
  • de Carvalho M, Scotto M, Lopes AAS, Swash M. Quantitating progression in ALS. Neurology64, 1783–1785 (2005).
  • de Carvalho M, Costa J, Swash M. Clinical trials in ALS: a review of the role of clinical and neurophysiological measurements. Amyotroph. Lateral Scler. Other Motor Neuron Disord.6, 202–212 (2005).
  • Kaufmann P, Levy G, Thompson JL et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology64, 38–43 (2005).
  • Miano B, Stoddard GJ, Davis S, Bromberg MB. Inter-evaluator reliability of the ALS functional rating scale. Amyotroph. Lateral Scler. Other Motor Neuron Disord.5, 235–239 (2004).
  • Moore DH, Miller RG, Group WS, Group ACS. ALSFRS as a measure of disease progression and a predictor of survival. Amyotroph. Lateral Scler. Other Motor Neuron Disord.4, 42 (2003).
  • Kalra S, Arnold D. Neuroimaging in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord.4, 243–248 (2003).
  • Graham JM, Papadakis N, Evans J et al. Diffusion tensor imaging for the assessment of upper motor neuron integrity in ALS. Neurology63, 2111–2119 (2004).
  • Rule RR, Suhy J, Schuff N et al. Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study. Amyotroph. Lateral Scler. Other Motor Neuron Disord.5, 141–149 (2004).
  • Bowen BC, Bradley WG. Amyotrophic lateral sclerosis: the search for a spectroscopic marker of upper motoneuron involvement. Arch. Neurol.58, 714–716 (2001).
  • Kalra S, Cashman NR, Caramanos Z, Genge A, Arnold DL. Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. AJNR Am. J. Neuroradiol.24, 476–480 (2003).
  • Vielhaber S, Kaufmann J, Kanowski M et al. Effect of creatine supplementation on metabolite levels in ALS motor cortices. Exp. Neurol.172, 377–382 (2001).
  • Camu W, Billiard M, Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurol. Scand.88, 18–25 (1993).
  • Beal MF, Ferrante RJ, Browne SE et al. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol.42, 644–654 (1997).
  • Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology62, 1758–1765 (2004).
  • Wiederkehr F, Wacker M, Vonderschmitt DJ. Analysis of immune complexes of cerebrospinal fluid by twoHdimensional gel electrophoresis. Electrophoresis10, 473–479 (1989).
  • Smith RG, Henry YK, Mattson MP, Appel SH. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Ann. Neurol.44, 696–699 (1998).
  • Jacobsson J, Jonsson PA, Andersen PM, Forsgren L, Marklund SL. Superoxide dismutase in CSF from amyotrophic lateral sclerosis patients with and without CuZn-superoxide dismutase mutations. Brain124, 1461–1466 (2001).
  • Strey CW, Spellman D, Stieber A et al. Dysregulation of stathmin, a microtubuleHdestabilizing protein, and upHregulation of Hsp25, Hsp27, and the antioxidant peroxiredoxin 6 in a mouse model of familial amyotrophic lateral sclerosis. Am. J. Pathol.165, 1701–1718 (2004).
  • Jokic N, Gonzalez de Aguilar G, Pradat PF et al. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann. Neurol.57, 553–556 (2005).
  • Sussmuth SD, Tumani H, Ecker D, Ludolph AC. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 β in cerebrospinal fluid and creatine kinase in serum. Neurosci. Lett.353, 57–60 (2003).
  • Kuncl RW, Bilak MM, Bilak SR et al. Pigment epithelium-derived factor is elevated in CSF of patients with amyotrophic lateral sclerosis. J. Neurochem.81, 178–184 (2002).
  • Jimenez-Jimenez FJ, Hernanz A, MedinaHAcebron S et al. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol. Scand.111, 114–117 (2005).
  • Brockington A, Wharton SB, Fernando M et al. Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol.65, 26–36 (2006).
  • Maragakis NJ, Dykes-Hoberg M, Rothstein JD. Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann. Neurol.55, 469–477 (2004).
  • McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve26, 459–470 (2002).
  • Hensley K, Floyd RA, Gordon B et al. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem.82, 365–374 (2002).
  • Tsuboi Y, Yamada T. Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry57, 859–861 (1994).
  • Sekizawa T, Openshaw H, Ohbo K et al. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J. Neurol. Sci.154, 194–199 (1998).
  • Baron P, Bussini S, Cardin V et al. Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve32, 541–544 (2005).
  • Apostolski S, Nikolic J, BugarskiHProkopljevic C et al. Serum and CSF immunological findings in ALS. Acta Neurol. Scand.83, 96–98 (1991).
  • Pullen AH, Demestre M, Howard RS, Orrell RW. Passive transfer of purified IgG from patients with amyotrophic lateral sclerosis to mice results in degeneration of motor neurons accompanied by Ca2+ enhancement. Acta Neuropathol.107, 35–46 (2004).
  • Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann. Neurol.52, 448–457 (2002).
  • Bogdanov M, Brown RH, Matson WR et al. Increased oxidative damage to DNA in ALS patients. Free Radic. Biol. Med.29, 652–658 (2000).
  • Dangond F, Hwang D, Camelo S et al. Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. Physiol. Genomics16, 229–239 (2003).
  • Jiang YM, Yamamoto M, Kobayashi Y et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann. Neurol.57, 236–251 (2005).
  • Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers9, 1–31 (2004).
  • Urbanczyk-Wochniak E, Luedemann A, Kopka J et al. Parallel analysis of transcript and metabolic profiles: a new approach in systems biology. EMBO Rep.4, 989–993 (2003).
  • Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotech.22, 245–252 (2004).
  • Brindle JT, Antti H, Holmes E et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nature Med.8, 1439–1444 (2002).
  • Keun HC, Ebbels TM, Bollard ME et al. Geometric trajectory analysis of metabolic responses to toxicity can define treatment specific profiles. Chem. Res. Toxicol.17, 579–587 (2004).
  • Volicer L, Langlais PJ, Matson WR, Mark KA, Gamache PH. Serotoninergic system in dementia of the Alzheimer type. Abnormal forms of 5-hydroxytryptophan and serotonin in cerebrospinal fluid. Arch. Neurol.42, 1158–1161 (1985).
  • Rozen S, Cudkowicz ME, Bogdanov M et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics1, 101–108 (2005).
  • Kell DB. Metabolomics and systesm biology: making sense of the soup. Curr. Opin. Microbiol.7, 296–307 (2004).
  • Kennedy RL, Lee Y, Van Roy B et al.Solving data mining problems through pattern recognition. Kennedy RL, Lee Y, Van Roy B, Reed CD, Lippman RP (Eds), Prentice Hall PTR, NJ, USA (1997).
  • Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science286, 531–537 (1999).
  • Eriksson L, Johansson E, Kettaneh-Wold N et al.Multi- and Megavariate Analysis: Principles and Applications. Eriksson L, Johansson E, Kettaneh-Wold N, Wold S (Eds), Umetrics Inc., NJ, USA (2001).
  • Anderson NL, Anderson NG. The human plasma proteome. Mol. Cell. Proteomics1, 845–867 (2002).
  • Dumont D, Noben J-P, Raus J, Stinissen P, Robben J. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics4, 2117–2124 (2004).
  • Tsuji T, Shiozaki A, Kohno R, Yoshizato K, Shimohama S. Proteomic profiling and neurodegeneration in Alzheimer’s disease. Neurochem. Res.27, 1245–1253 (2002).
  • Choe LH, Dutt MJ, Relkin N, Lee KH. Studies of potential cerebrospinal fluid molecular markers for Alzheimer’s disease. Electrophoresis23, 2247–2251 (2002).
  • Allen S, Heath PR, Kirby J et al. Analysis of the cytosoloic proteome in a cell-culture model of familial amyotrophic lateral sclerosis reveals alterations to the proteasome, antioxidant defences and nitric oxide synthetic pathways. J. Biol. Chem.278, 6371–6383 (2003).
  • Luo X, Carlson KA, Wojna V et al. Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment. Neurology60, 1931–1937 (2003).
  • Blennow K. CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment. Expert Rev. Mol. Diagn.5, 661–672 (2005).
  • Palma A, de Carvalho M, Barata N et al. Biochemical characterization of plasma in amyotrophic lateral sclerosis: amino acid and protein composition. Amyotroph. Lateral Scler. Other Motor Neuron Disord.6, 104–110 (2005).
  • Ramstrom M, Ivonin I, Johansson A et al. Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometry. Proteomics4, 4010–4018 (2005).
  • Ranganathan S, Williams E, Ganchev P et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J. Neurochem.95, 1461–1471 (2005).
  • Provost F, Buchanan B. Inductive policy: the pragmatics of bias selection. Machine Learning20, 35–61 (1995).
  • Marcinkiewicz M, Touraine P, Chretien M. Pan-neuronal mRNA expression of the secretory polypeptide 7B2. Neurosci. Lett.177, 91–94 (1994).
  • Hwang JR, Lindberg I. Inactivation of the 7B2 inhibitory CT peptide depends on a functional furin cleavage site. J. Neurochem.79, 437–444 (2001).
  • Gonatas NK. Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis. Am. J. Pathol.140, 731–737 (1992).
  • van Welsem ME. The relationship between Bunina bodies, skein-like inclusions and neuronal loss in amyotrophic lateral sclerosis. Acta Neuropathol.103, 583–589 (2002).
  • Schreiber G. The evolution of transthyretin synthesis in the choroid plexus. Clin. Chem. Lab. Med.40, 1200–1210 (2002).
  • Power DM. Evolution of the thyroid hormone-binding protein, transthyretin. Gen. Comp. Endocrinol.119, 241–255 (2000).
  • Monaco HL. The transthyretin-retinol-binding protein complex. Biochim Biophys. Acta1482, 65–72 (2000).
  • Serot JM, Christmann D, Dubost T, Couturier M. Cerebrospinal fluid transthyretin: aging and late onset Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry63, 506–508 (1997).
  • Stein TD, Anders NJ, DeCarli C et al. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPsw mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J. Neurosci.24, 7707–7717 (2004).
  • Winkleman J, Wybenga DR, Ibbott FA. Phenotyping of hyperlipoproteinemias: effect on electrophoretic pattern of serum storage at ambient, refrigerator or freezing temperatures. Clin. Chem.16, 507–511 (1970).
  • Hulmes JD, Bethea D, Ho K et al. An investigation of plasma collection, stabilization, and storage procedures for proteomic analysis of clinical samples. Clin. Proteomics1, 17–31 (2004).
  • Ranganathan S, Polshyna A, Nicholl G, Lyons-Weiler J, Bowser R. Assessment of protein stability in cerebrospinal fluid using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry protein profiling. Clin. Proteomics (2006) (In Press).
  • Zhang J, Goodlett D, Quinn JF et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis.7, 125–133 (2005).
  • Zhang J, Goodlett DR, Peskind ER et al. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol. Aging26, 207–227 (2005).
  • Yuan X, Desiderio DM. Human cerebrospinal fluid peptidomics. J. Mass Spectrom.40, 176–181 (2005).
  • Hand CK, Khoris J, Salachas F et al. A novel locus for familial amyotrophic lateral sclerosis on chromosome 18q. Am. J. Hum. Genet.70, 251–256 (2002).
  • Hentati A, Ouahchi K, Pericak-Vance MA et al. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics2, 55–60 (1998).
  • Ruddy DM, Parton MJ, Al-Chalabi A et al. Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q. Am. J. Hum. Genet.73, 390–396 (2003).
  • Sapp PC, Hosler BA, McKenna-Yasek D et al. Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am. J. Hum. Genet.73, 397–403 (2003).
  • Nishimura AL, Mitne-Neto M, Silva HC et al. A novel locus for late onset amyotrophic lateral sclerosis/motor neurone disease variant at 20q13. J. Med. Genet.41, 315–320 (2004).
  • Nishimura AL, Mitne-Neto M, Silva HC et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet.75, 822–831 (2004).
  • Clark LN, Poorkaj P, Wszolek Z et al. Pathogenic implications of mutations in the tau gene in palido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc. Natl Acad. Sci. USA95, 13103–13107 (1998).
  • Wilhelmsen KC, Forman MS, Rosen HJ et al. 17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and α-synuclein inclusions. Arch. Neurol.61, 398–406 (2004).
  • Dupuis L, Gonzalez de Aguilar JL, di Scala F et al. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol. Dis.10, 358–365 (2002).
  • Almer G, Teismann P, Stevic Z et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology58, 1277–1279 (2002).
  • Beuche W, Yushchenko M, Mader M et al. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport11, 3419–3422 (2000).
  • Oteiza PI, Uchitel OD, Carrasquedo F et al. Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients. Neurochem. Res.22, 535–539 (1997).
  • Ferrante RJ, Browne SE, Shinobu LA et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem.69, 2064–2074 (1997).
  • Tohgi H, Abe T, Yamazaki K et al. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann. Neurol.46, 129–131 (1999).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.